Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular and superficial) of high risk and/or locally advanced basal cell carcinoma, in an open label prospective case series clinical trial

Vismodegib demonstrated 60% response rates in the ERIVANCE trial. Basal cell carcinoma (BCC) has various histopathologies. Their impact on response is unclear.

Source: Journal of the American Academy of Dermatology - December 9, 2019 Category: Dermatology Authors: Scott W. Fosko, Melinda B. Chu, Eric Armbrecht, Tim Galperin, Geoffrey A. Potts, Adam Mattox, Anastasia Kurta, Kristen Polito, Jordan B. Slutsky, Nicole M. Burkemper, M Yadira Hurley Source Type: research